Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 19/20 | 0.50 |
| ▸ | MAP2 | P11137 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320910 | 1.00 | RORC (0.50) | RORCMAP2CYP2C9CYP2C19 | |
| SCHEMBL14744191 | 0.91 | RORC (0.44) | RORCMAP2CYP2C9CYP2C19 | |
| SCHEMBL14744242 | 0.90 | RORC (0.48) | RORCMAP2CYP2C9CYP2C19 | |
| SCHEMBL14744452 | 0.86 | RORC (0.49) | RORCMAP2CYP2C9CYP2C19 | |
| SCHEMBL14744245 | 0.83 | RORC (0.45) | RORCMAP2 | |
| SCHEMBL30321020 | 0.83 | RORC (0.45) | RORCMAP2 | |
| SCHEMBL14744380 | 0.82 | ALOX5AP (0.47) | RORCMAP2CYP2C9 | |
| SCHEMBL30320922 | 0.81 | RORC (0.46) | RORCMAP2 | |
| SCHEMBL20943238 | 0.80 | RORC (0.56) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14744335 | 0.79 | GRIA1 (0.39) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3476829-B1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | UNIV FUDAN (CN) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021228215-A1 | BIARYL COMPOUND CAPABLE OF SERVING AS RORγ REGULATOR | 上海辉启生物医药科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| US-10851050-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-12-01 | — | — | US | disclosed |
| US-20200239411-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | UNIV FUDAN (CN) | 2020-07-30 | — | — | US | disclosed |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | FUDAN UNIVERSITY (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3476829-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | Fudan University (CN) | 2019-05-01 | — | — | EP | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239411-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | RORC, RORB, RORA | RORC 1/4885MAP2 941/4885CYP2C9 161/4885 |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | RORC, RORB, RORA | RORC 1/4885MAP2 783/4885CYP2C9 184/4885 |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | RORC 1/4885MAP2 783/4885CYP2C9 184/4885 |
| US-10851050-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | RORC 1/4885MAP2 941/4885CYP2C9 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.